• Je něco špatně v tomto záznamu ?

Fenofibrate Attenuates Hypertension in Goldblatt Hypertensive Rats: Role of 20-Hydroxyeicosatetraenoic Acid in the Nonclipped Kidney

A. Sporková, V. Čertíková Chábová, Š. Doleželová, Š. Jíchová, L. Kopkan, Z. Vaňourková, E. Kompanowska-Jezierska, J. Sadowski, H. Maxová, L. Červenka,

. 2017 ; 353 (6) : 568-579. [pub] 20170412

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023117

BACKGROUND: There is vast evidence that the renin-angiotensin system is not the sole determinant of blood pressure (BP) elevation in human renovascular hypertension or the relevant experimental models. This study tested the hypothesis that kidney deficiency of 20-hydroxyeicosatetraenoic acid (20-HETE), a product of cytochrome P450 (CYP)-dependent ω-hydroxylase pathway of arachidonic acid metabolism, is important in the pathophysiology of the maintenance phase of 2-kidney, 1-clip (2K1C) Goldblatt hypertension. MATERIALS AND METHODS: In 2K1C Goldblatt rats with established hypertension, angiotensin II, angiotensin 1-7, 20-HETE concentrations and gene expression of CYP4A1 enzyme (responsible for 20-HETE formation) of the nonclipped kidney were determined. We examined if 14 days׳ administration of fenofibrate, a lipid-lowering drug, would increase CYP4A1 gene expression and renal 20-HETE formation, and if increased 20-HETE concentrations in the nonclipped kidney would decrease BP (telemetric measurements). RESULTS: CYP4A1 gene expression, 20-HETE and angiotensin 1-7 concentrations were lower and angiotensin II levels were higher in the nonclipped kidney of 2K1C rats than in sham-operated rats. Fenofibrate increased CYP4A1 gene expression and 20-HETE concentration in the nonclipped kidney and significantly decreased BP in 2K1C rats but did not restore it to normotensive range. The treatment did not change BP in sham-operated rats. CONCLUSIONS: Our results suggest that alterations in the RAS and CYP-dependent ω-hydroxylase metabolites of arachidonic acid in the nonclipped kidneys are both important in the pathophysiology of the maintenance phase of 2K1C Goldblatt hypertension. Therefore, fenofibrate treatment effectively attenuated hypertension, probably via stimulation of 20-HETE formation in the nonclipped kidney.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023117
003      
CZ-PrNML
005      
20180930132735.0
007      
ta
008      
170720s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.amjms.2017.04.009 $2 doi
035    __
$a (PubMed)28641720
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sporková, Alexandra $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Fenofibrate Attenuates Hypertension in Goldblatt Hypertensive Rats: Role of 20-Hydroxyeicosatetraenoic Acid in the Nonclipped Kidney / $c A. Sporková, V. Čertíková Chábová, Š. Doleželová, Š. Jíchová, L. Kopkan, Z. Vaňourková, E. Kompanowska-Jezierska, J. Sadowski, H. Maxová, L. Červenka,
520    9_
$a BACKGROUND: There is vast evidence that the renin-angiotensin system is not the sole determinant of blood pressure (BP) elevation in human renovascular hypertension or the relevant experimental models. This study tested the hypothesis that kidney deficiency of 20-hydroxyeicosatetraenoic acid (20-HETE), a product of cytochrome P450 (CYP)-dependent ω-hydroxylase pathway of arachidonic acid metabolism, is important in the pathophysiology of the maintenance phase of 2-kidney, 1-clip (2K1C) Goldblatt hypertension. MATERIALS AND METHODS: In 2K1C Goldblatt rats with established hypertension, angiotensin II, angiotensin 1-7, 20-HETE concentrations and gene expression of CYP4A1 enzyme (responsible for 20-HETE formation) of the nonclipped kidney were determined. We examined if 14 days׳ administration of fenofibrate, a lipid-lowering drug, would increase CYP4A1 gene expression and renal 20-HETE formation, and if increased 20-HETE concentrations in the nonclipped kidney would decrease BP (telemetric measurements). RESULTS: CYP4A1 gene expression, 20-HETE and angiotensin 1-7 concentrations were lower and angiotensin II levels were higher in the nonclipped kidney of 2K1C rats than in sham-operated rats. Fenofibrate increased CYP4A1 gene expression and 20-HETE concentration in the nonclipped kidney and significantly decreased BP in 2K1C rats but did not restore it to normotensive range. The treatment did not change BP in sham-operated rats. CONCLUSIONS: Our results suggest that alterations in the RAS and CYP-dependent ω-hydroxylase metabolites of arachidonic acid in the nonclipped kidneys are both important in the pathophysiology of the maintenance phase of 2K1C Goldblatt hypertension. Therefore, fenofibrate treatment effectively attenuated hypertension, probably via stimulation of 20-HETE formation in the nonclipped kidney.
650    _2
$a zvířata $7 D000818
650    _2
$a fenofibrát $x farmakologie $x terapeutické užití $7 D011345
650    _2
$a kyseliny hydroxyeikosatetraenové $x nedostatek $7 D006893
650    _2
$a renovaskulární hypertenze $x farmakoterapie $x patofyziologie $7 D006978
650    _2
$a hypolipidemika $x farmakologie $x terapeutické užití $7 D000960
650    _2
$a ledviny $x účinky léků $x metabolismus $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
655    _2
$a časopisecké články $7 D016428
700    1_
$a Čertíková Chábová, Věra $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Doleželová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. $7 xx0227631
700    1_
$a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kopkan, Libor $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Vaňourková, Zdeňka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kompanowska-Jezierska, Elzbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
700    1_
$a Maxová, Hana $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: luce@medicon.cz.
773    0_
$w MED00000305 $t The American journal of the medical sciences $x 1538-2990 $g Roč. 353, č. 6 (2017), s. 568-579
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28641720 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20180930133218 $b ABA008
999    __
$a ok $b bmc $g 1238798 $s 984030
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 353 $c 6 $d 568-579 $e 20170412 $i 1538-2990 $m The American journal of the medical sciences $n Am J Med Sci $x MED00000305
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace